KRAS and colorectal cancer: Further, Gao et al. confirmed superior sensitivity of the KRAS StripAssay relative to Sanger and pyrosequencing in FFPE colorectal cancer tissue, detecting mutations at lower allele frequencies and thus increasing mutation detection rates critical for effective therapy and trial inclusion [185].